Details
Stereochemistry | ACHIRAL |
Molecular Formula | Cr |
Molecular Weight | 51.9961 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cr]
InChI
InChIKey=VYZAMTAEIAYCRO-UHFFFAOYSA-N
InChI=1S/Cr
Nearly 60 years ago, chromium, as the trivalent ion, was proposed to be an essential element, but the results of new studies indicate that chromium currently can only be considered pharmacologically active and not an essential element. Chromium is a mineral that humans need in very small quantities. Good sources include broccoli, liver, and brewers' yeast. Taking chromium by mouth is effective for preventing chromium deficiency. It is also taken by mouth for depression, Turner's syndrome, polycystic ovary syndrome (PCOS), lowering "bad" cholesterol, raising "good" cholesterol in people taking heart medications called beta blockers, obesity, metabolic syndrome, heart attack, schizophrenia, bipolar disorder, binge eating disorder, and a disease called reactive hypoglycemia. Chromium has been marketed as an agent to reduce body mass and develop muscle; however, such marketing claims are no longer allowed in the United States because they are not supported by experiments. Trivalent chromium has also been proposed as a therapeutic agent to increase insulin sensitivity and affect lipid metabolism. Although effective in certain rodent models, beneficial effects in humans have not been unequivocally established.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats. | 2001 Jan |
|
Effect of chromium picolinate on histopathological alterations in STZ and neonatal STZ diabetic rats. | 2003 Jul-Sep |
|
Chromium inhibits transcription from polycyclic aromatic hydrocarbon-inducible promoters by blocking the release of histone deacetylase and preventing the binding of p300 to chromatin. | 2004 Feb 6 |
|
A comparison of the insulin-sensitive transport of chromium in healthy and model diabetic rats. | 2004 Mar |
|
Effect of chromium on the insulin resistance in patients with type II diabetes mellitus. | 2005 |
|
[Effects of chromium supplementation on IRS-1 expression of skeletal muscle in diabetic rats]. | 2005 Jan |
|
[Regulatory effects of micronutrient complex on the expression of Th1 and Th2 cytokines in diabetic C57BL mice]. | 2005 Jan |
|
An ecological study of the association of environmental chemicals on breast cancer incidence in Texas. | 2005 Jul |
|
Effect of chromium picolinate on modified forced swimming test in diabetic rats: involvement of serotonergic pathways and potassium channels. | 2006 Feb |
|
Effects of 12 metal ions on iron regulatory protein 1 (IRP-1) and hypoxia-inducible factor-1 alpha (HIF-1alpha) and HIF-regulated genes. | 2006 Jun 15 |
|
Functional characteristics of NaS2, a placenta-specific Na+-coupled transporter for sulfate and oxyanions of the micronutrients selenium and chromium. | 2006 Jun-Jul |
|
Matrix metalloproteinases and their inhibitors as biomarkers for metal toxicity in vitro. | 2006 Oct |
|
Oxidative stress and genotoxic effects in gill and kidney of Anguilla anguilla L. exposed to chromium with or without pre-exposure to beta-naphthoflavone. | 2006 Sep 19 |
|
Characterization and distribution of the selected metals in the scalp hair of cancer patients in comparison with normal donors. | 2007 Sep |
|
Combination of chromium and biotin improves coronary risk factors in hypercholesterolemic type 2 diabetes mellitus: a placebo-controlled, double-blind randomized clinical trial. | 2007 Spring |
|
Arsenite and cadmium, but not chromium, induce NAD(P)H:quinone oxidoreductase 1 through transcriptional mechanisms, in spite of post-transcriptional modifications. | 2008 Aug |
|
Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/- HCT116 colon cancer cells. | 2008 Feb 1 |
|
Cholesterol efflux and the effect of combined treatment with niacin and chromium on aorta of hyperlipidemic rat. | 2008 Jan |
|
Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. | 2008 Jan |
|
Blood pressure lowering effects of niacin-bound chromium(III) (NBC) in sucrose-fed rats: renin-angiotensin system. | 2008 Jul |
|
Chromium (VI) induces insulin resistance in 3T3-L1 adipocytes through elevated reactive oxygen species generation. | 2008 Jun |
|
Deposition of nickel, chromium, and cobalt on the skin in some occupations - assessment by acid wipe sampling. | 2008 Jun |
|
Gene expression profiles in rainbow trout, Onchorynchus mykiss, exposed to a simple chemical mixture. | 2008 Mar |
|
Chromium (D-phenylalanine)3 supplementation alters glucose disposal, insulin signaling, and glucose transporter-4 membrane translocation in insulin-resistant mice. | 2008 Oct |
|
Effect of chromium supplementation on the diabetes induced-oxidative stress in liver and brain of adult rats. | 2009 Dec |
|
Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury. | 2009 Jan |
|
Chromium(III) induces oxidative stress in goldfish liver and kidney. | 2009 Jun 4 |
|
Multiple metals predict prolactin and thyrotropin (TSH) levels in men. | 2009 Oct |
|
Chromium attenuates high-fat diet-induced nonalcoholic fatty liver disease in KK/HlJ mice. | 2010 Jul 2 |
|
Maternal dietary chromium restriction programs muscle development and function in the rat offspring. | 2010 Mar |
|
Evaluation of insulin binding and signaling activity of newly synthesized chromium(III) complexes in vitro. | 2010 Mar-Apr |
|
Simultaneous analysis of the local and systemic immune responses in mice to study the occupational asthma mechanisms induced by chromium and platinum. | 2010 Nov 9 |
|
Chromium (VI) inhibits mouse metallothionein-I gene transcription by modifying the transcription potential of the co-activator p300. | 2011 Apr |
|
Chromium improves production and alters metabolism of early lactation cows in summer. | 2011 Feb |
|
Chromium (D-phenylalanine)3 alleviates high fat-induced insulin resistance and lipid abnormalities. | 2011 Jan |
|
Cardioprotective effects of selenium on chromium (VI)-induced toxicity in female rats. | 2011 Mar |
|
Comparison of gene expression profiles in chromate transformed BEAS-2B cells. | 2011 Mar 18 |
|
The effects of chromium complex and level on glucose metabolism and memory acquisition in rats fed high-fat diet. | 2011 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npc/chromium.html
Curator's Comment: Chromium is also used intravenously (by IV) as a supplement in nutritional IV drips. https://www.webmd.com/vitamins/ai/ingredientmono-932/chromium
The currently accepted value for chromium dietary intake is 25 mcg/day for women and 35 mcg/day for men. Daily dosages used in clinical trials for periods of up to 9 months range as follows: brewer's yeast up to 400 mcg/day; chromium chloride 50 to 600 mcg/day; chromium nicotinate 200 to 800 mcg/day; chromium picolinate 60 to 1,000 mcg/day. The potential for genotoxic effects exists at higher dosages.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 581
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 586
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 583
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 578
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
NCI_THESAURUS |
C637
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 590
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 588
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 579
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 584
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 580
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
NCI_THESAURUS |
C896
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 582
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 589
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 585
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
NDF-RT |
N0000185508
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 591
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 587
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID3031022
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
2496
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
N0000171131
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
C370
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
0R0008Q3JB
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
m3505
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
910
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
100000090349
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
28073
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
N0000184306
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
DB11136
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
SUB13362MIG
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
D002857
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
0R0008Q3JB
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
231-157-5
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
23976
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | |||
|
N0000175629
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY | Increased Histamine Release [PE] | ||
|
7440-47-3
Created by
admin on Mon Mar 31 18:23:21 GMT 2025 , Edited by admin on Mon Mar 31 18:23:21 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)